{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:09:04Z","timestamp":1778962144370,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eimce.2025.503050","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:53:09Z","timestamp":1768312389000},"page":"503050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing CLIA for QuantiFERON\u00ae-CMV testing: Optimizing cellular immune response against cytomegalovirus"],"prefix":"10.1016","volume":"44","author":[{"given":"Juliana","family":"Esperalba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Arnedo-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Rando-Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Revilla-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aroa","family":"Gomez-Brey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Nadal-Bar\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Marquez-Algaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Sandiumenge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Larrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e0s","family":"Pumarola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Len","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2025.503050_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eimc.2009.07.008","article-title":"Direct and indirect effects of cytomegalovirus: can we prevent them?","volume":"28","author":"Razonable","year":"2010","journal-title":"Enferm Infecc Microbiol Cl\u00edn"},{"key":"10.1016\/j.eimce.2025.503050_bib0100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.eimce.2025.503050_bib0105","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cnet state of immunosuppression\u201d","volume":"73","author":"Roberts","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2025.503050_bib0110","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.eimce.2025.503050_bib0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.eimce.2025.503050_bib0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/erm.10.109","article-title":"QuantiFERON\u00ae-CMV assay for the assessment of cytomegalovirus cell-mediated immunity","volume":"11","author":"Giulieri","year":"2011","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.eimce.2025.503050_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2024.100875","article-title":"Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update","volume":"38","author":"Ruiz-Arabi","year":"2024","journal-title":"Transplant Rev"},{"key":"10.1016\/j.eimce.2025.503050_bib0130","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimce.2025.503050_bib0135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.eimce.2025.503050_bib0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial","volume":"74","author":"P\u00e1ez-Vega","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2025.503050_bib0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON\u00ae-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimce.2025.503050_bib0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/apm.13025","article-title":"Comparative evaluation of CLIA and EIA for Quantiferon-TB Gold Plus","volume":"128","author":"Brantestig","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.eimce.2025.503050_bib0155","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00603-21","article-title":"Evaluation of the fully automated chemiluminescence analyzer liaison XL for the performance of the QuantiFERON-TB gold plus assay in an area with a low incidence of tuberculosis","volume":"59","author":"Fern\u00e1ndez-Huerta","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.eimce.2025.503050_bib0160","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/cid\/ciad030","article-title":"Assessing the diagnostic performance of new commercial interferon-\u03b3 release assays for mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"76","author":"Ortiz-Brizuela","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2025.503050_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105550","article-title":"Evaluation of the fully automated LIAISON\u00aeXL chemiluminescence analyzer for QuantiFERON\u00ae-CMV testing in transplant recipients","volume":"166","author":"Mafi","year":"2023","journal-title":"J Clin Virol"},{"key":"10.1016\/j.eimce.2025.503050_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2024.105651","article-title":"QuantiFERON-CMV assay by chemiluminescence immunoassay: is it more suitable for real-live monitoring of transplant patients?","volume":"171","author":"Fern\u00e1ndez-Moreno","year":"2024","journal-title":"J Clin Virol"},{"key":"10.1016\/j.eimce.2025.503050_bib0175","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00159-20","article-title":"Evaluation of QuantiFERON-TB Gold Plus on Liaison XL in a low-tuberculosis-incidence setting","volume":"58","author":"De Maertelaere","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.eimce.2025.503050_bib0180","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00780-20","article-title":"QuantiFERON-TB Gold Plus with chemiluminescence immunoassay: do we need a higher cutoff?","volume":"58","author":"Bisognin","year":"2020","journal-title":"J Clin Microbiol"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X25002424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X25002424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:50:44Z","timestamp":1778961044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X25002424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2529993X25002424"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2025.503050","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing CLIA for QuantiFERON\u00ae-CMV testing: Optimizing cellular immune response against cytomegalovirus","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2025.503050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"503050"}}